Back

A deeper dive into key ODYSSEY OUTCOMES results and their impact on patient management.

28 August 2018 (10:25 - 10:35)
Organised by:
Congress Presentation Part of: From ODYSSEY OUTCOMES results to clinical practice - Identifying patients who may benefit most from PCSK9 inhibition Lipids ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Gregory Schwartz

University of Colorado School of Medicine, Aurora (United States of America)

2 More presentations in this session

Presentation thumbnail
From identification of high CV risk patients to treatment with PCSK9i: learnings from ODYSSEY OUTCOMES.
Professor A. Zeiher (Frankfurt, DE)
Presentation thumbnail
Interaction with the audience
Professor A. Zeiher (Frankfurt, DE)

Access the full session

Session thumbnail
From ODYSSEY OUTCOMES results to clinical practice - Identifying patients who may benefit most from PCSK9 inhibition

The Event

Event poster

ESC Congress 2018

28 August 2018 10:25 CET
You may be interested in
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
31 August 2025
thumbnail
Congress Presentation
2 September 2019
thumbnail
Congress Presentation
Automated digital counselling promotes therapeutic change in mental health in patients with chronic heart failure or chronic kidney disease: ODYSSEE-vCHAT study
1 September 2024
thumbnail
Congress Presentation
OCEAN(a)-DOSE Extension
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources